Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136996 | 0.90 | PLAU (0.40) | GPR119MAPTNPSR1ALDH1A1 | |
| SCHEMBL1136879 | 0.80 | L3MBTL1 (0.49) | GPR119MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL1136878 | 0.80 | L3MBTL1 (0.49) | GPR119MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL16095464 | 0.69 | SMN1; SMN2 (0.58) | GPR119MEN1KMT2ANPSR1 | |
| SCHEMBL23249889 | 0.69 | SMN1; SMN2 (0.58) | GPR119MEN1KMT2ANPSR1 | |
| SCHEMBL13303078 | 0.69 | SMN1; SMN2 (0.53) | GPR119MEN1KMT2A | |
| SCHEMBL785781 | 0.69 | CCR5 (0.58) | GPR119 | |
| SCHEMBL803663 | 0.69 | JAK2 (0.54) | GPR119MEN1KMT2A | |
| SCHEMBL1136994 | 0.68 | SCNN1A (0.46) | MAPTNPSR1ALDH1A1 | |
| SCHEMBL1136991 | 0.68 | SCNN1A (0.46) | MAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318935-B2 | Organic compounds 75074 | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| EP-2332933-A1 | Epithelial sodium channel (ENaC) inhibitors | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2155721-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-23 | — | — | EP | disclosed |
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2155721-A1 | ORGANIC COMPOUNDS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008135557-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105660-A1 | ORGANIC COMPOUNDS75074 | SCNN1A, TRPM4, TRPV4 | GPR119 526/4885MEN1 707/4885KMT2A 4259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.